Generics

Imitrex Nasal Spray and its generic equivalents had a market value of approximately $53.3 million for the 12 months ended December 2020, according to IQVIA.

Lannett expects to start a pivotal trial for its biosimilar Lantus early in 2022, with expectations of a launch in 2023.

Zydus Cadila's generic Pamelor is indicated to treat such mental/mood problems as depression.

Potassium chloride oral solution had a market value of $56 million, according to IQVIA January 2021 data.

Fresenius Kabi is launching the first to market generic for Foscavir, a treatment for immune-compromised patients.

Nitazoxanide tablets had a market value of $56 million, according to IQVIA January 2021 data.

The Insud Pharmaceuticals division is launching its generics of Alkeran and Prometrium, which had market sizes of $20.4 million and $74.8 million for the year ended December 2020, according to IQVIA data.

ANI's acquisition of New Jersey-based Novitium for $163.5 million will strengthen its generics business and diversify its portfolio, according to the company.